4/17
08:02 pm
crdf
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting [Yahoo! Finance]
Medium
Report
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting [Yahoo! Finance]
4/17
04:01 pm
crdf
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Low
Report
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
4/9
04:16 pm
crdf
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth [Yahoo! Finance]
Medium
Report
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth [Yahoo! Finance]
4/9
04:01 pm
crdf
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Medium
Report
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
3/20
07:22 am
crdf
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer [Yahoo! Finance]
3/19
07:00 am
crdf
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Low
Report
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
3/4
02:31 am
crdf
Medium
Report
2/26
04:22 pm
crdf
Cardiff Oncology to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Cardiff Oncology to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]
2/26
04:01 pm
crdf
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Low
Report
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
2/26
04:52 am
crdf
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC [Yahoo! Finance]
Low
Report
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC [Yahoo! Finance]
2/25
10:24 am
crdf
Cardiff Oncology (CRDF) had its price target lowered by Piper Sandler from $10.00 to $6.00. They now have an "overweight" rating on the stock.
Medium
Report
Cardiff Oncology (CRDF) had its price target lowered by Piper Sandler from $10.00 to $6.00. They now have an "overweight" rating on the stock.
2/24
05:35 pm
crdf
Cardiff Oncology: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Cardiff Oncology: Q4 Earnings Snapshot [Yahoo! Finance]
2/24
04:30 pm
crdf
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Medium
Report
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
2/19
07:34 am
crdf
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/19
07:00 am
crdf
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
1/28
07:19 am
crdf
Cardiff Oncology (NASDAQ:CRDF) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Cardiff Oncology (NASDAQ:CRDF) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/28
02:26 am
crdf
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript [Seeking Alpha]
High
Report
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript [Seeking Alpha]
1/27
07:05 am
crdf
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
High
Report
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
1/27
07:00 am
crdf
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
High
Report
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development